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Abstract: Diabetic macular edema is the major cause of visual acuity impairment in   diabetic 
patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser 
  photocoagulation represents the recommended treatment. It has been demonstrated that vascular 
endothelial growth factor (VEGF) plays a key role in the pathogenesis of diabetic macular edema 
by mediating vascular permeability and accumulation of intracellular and extracellular fluid, and 
thereby represents an appealing candidate as a therapeutic target for the treatment of diabetic 
macular edema. The advent of intravitreal anti-VEGF drugs has opened up a new era for the 
management of diabetic macular edema. At present, three anti-VEGF substances are available 
for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. The aim of this review 
is to summarize the evidence supporting the use of ranibizumab in clinical   practice. Most of 
the studies analyzed in this review are prospective, controlled clinical trials that have focused 
on documenting the therapeutic effect of ranibizumab and its safety, providing encouraging 
results.
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Introduction
Diabetic macular edema is generally defined as retinal thickening or the presence of 
hard exudates within one disk diameter from the center of the macula secondary to 
diabetic retinopathy.1,2 It is the major cause of visual acuity impairment in diabetic 
patients,3 and the exact etiopathogenesis remains unknown. Currently, retinal laser 
photocoagulation is the recommended treatment for clinically significant diabetic 
macular edema because it is the only treatment supported by a large clinical randomized, 
controlled trial.4 Nevertheless, laser treatment has a limited effect, resulting in 
functional improvement and anatomical regression of diabetic macular edema in a 
subset of patients.
Recently, many authors have stressed the role that vascular endothelial growth   factor 
(VEGF) plays in promoting vascular permeability and accumulation of intracellular 
and extracellular fluid by disrupting the intercellular tight junctions normally present 
between retinal endothelial cells.5–10
Different molecules involved in the pathway of VEGF transcription and activation are 
being tested or are available for routine clinical use. Three anti-VEGF drugs are   currently 
available for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. New 
interesting therapeutic approaches are represented by the administration of bevasiranib or 
rapamycin. The aim of this review is to discuss the published data regarding intravitreal 
ranibizumab in the treatment of diabetic macular edema.
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1303
REVIEw
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S17423Clinical Ophthalmology 2011:5
Ranibizumab
Ranibizumab is an antigen-binding fragment derived from a 
humanized anti-VEGF antibody that inhibits all biologically 
active isoforms and active proteolytic fragments of VEGF-A. 
Many clinical investigations have demonstrated the efficacy 
of ranibizumab in the treatment of diabetic macular edema.
Initial studies
Chun et al reported the first pilot study exploring the effects 
of two dosing regimens of ranibizumab in eyes affected by 
clinically significant diabetic macular edema.11 Ten patients 
were enrolled, with five receiving ranibizumab 0.3 mg and 
five receiving ranibizumab 0.5 mg at baseline and at one and 
two months. All patients completed the 24-month follow-up 
period. At month 3, 40% of patients gained more than 
15   letters, 50% gained more than 10 letters, and 80% obtained 
an improvement of at least one letter in best corrected visual 
acuity (BCVA). After three months, the mean decrease 
in central retinal thickness was 45.3 µm and 197.8 µm in 
the low-dose group and high-dose group, respectively. 
Intravitreal injections of ranibizumab were generally well 
tolerated, and no systemic adverse events were reported.
Nguyen et al investigated the role of ranibizumab in 
diabetic macular edema in a nonrandomized study.12 Ten 
patients with chronic diabetic macular edema received 
intraocular injections of 0.5 mg of ranibizumab at baseline 
and at one, two, four, and six months. A dose of 0.5 mg 
was chosen because it was the highest dose available and 
had documented safety. The main outcomes measured were 
changes in BCVA and central retinal thickness, as assessed 
by optical coherence tomography measurement at the seven-
month examination. Compared with baseline, mean foveal 
thickness showed a meaningful reduction, decreasing from 
503 µm to 257 µm, with a reduction of 85% of the excess 
foveal thickness present at baseline. At the nine-month visit, 
there was a worsening of diabetic macular edema compared 
with the seven-month visit, but retinal thickness did not return 
to baseline levels. The authors did not expect improvement 
of visual function in the selected patients because of the 
chronicity of diabetic macular edema and because the 
patients enrolled were characterized by lack of response to 
other treatments. However, the mean and median values of 
BCVA improved at seven months by 12.3 and 11 letters, 
respectively. Improvement in foveal thickening correlated 
with improvement in visual acuity at each study visit. The 
injections were well tolerated with no ocular or systemic 
adverse events.
READ-2 study
More recently, the results of the READ-2 study were 
  published. READ-2 is a prospective, randomized, inter-
ventional, multicenter clinical trial designed to compare 
ranibizumab with focal/grid laser, alone or in combination, 
for the treatment of diabetic macular edema.13,14 One 
hundred and twenty-six patients were randomized to receive 
0.5 mg of ranibizumab, focal/grid laser photocoagulation, 
or a combination of 0.5 mg of ranibizumab and focal/grid 
laser. In the ranibizumab group, 42 patients received 0.5 mg 
at baseline and months 1, 3, and 5. In the laser group, 
42 patients received focal/grid laser photocoagulation at 
baseline and month 3 if needed (center subfield thickness 
was .250 µm). In the combined therapy group, 42 patients 
received a combination of 0.5 mg of ranibizumab and focal/
grid laser at baseline and month 3. The primary outcome 
was the change in BCVA at month 6 in comparison with 
baseline values. After six months, the ranibizumab group 
showed a significant improvement in mean BCVA com-
pared with patients receiving focal/grid laser. BCVA in 
the group receiving combined therapy was not statistically 
different from the first two groups. A resolution of 50%, 
33%, and 45% of excess foveal thickening was documented 
in the ranibizumab, laser, and combined therapy groups, 
respectively. After six months, for the two years of 
follow-up, if retreatment criteria were met, all subjects could 
be treated with ranibizumab. In the ranibizumab group, 
BCVA improved from 7.4 letters at six-month follow-up to 
7.7 letters at the end of the 24-month follow-up. The laser 
group improved BCVA from 0.5 letters to 5.1 letters at the 
end of follow-up, and the combined therapy group patients 
showed an improvement in BCVA of 6.8 letters at month 24, 
compared with 3.8 letters in the same patients at month 6. 
These data demonstrate that intravitreal ranibizumab is 
effective in the treatment of recurrent and persistent diabetic 
macular edema and that the improvement of visual acuity 
could be maintained during a follow-up of two years. This 
study also showed that ranibizumab is associated with sig-
nificant improvement in patients who previously received 
only laser photocoagulation.
Finally, this study demonstrates that intravitreal injections 
combined with laser treatment are effective in reducing the 
frequency of injections without impairment of visual acuity at 
the end of two years of follow-up. Indeed, the mean number 
of injections was 9.3, 4.4, and 2.9 in the ranibizumab, laser, 
and combined therapy groups, out of a maximum of 13, nine, 
and six possible injections, respectively.
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RISE and RIDE studies
RISE and RIDE are Phase III, double-masked, multicenter, 
randomized, sham injection-controlled studies evaluating 
the efficacy and safety of ranibizumab injections in patients 
with diabetic macular edema.15 Recruited patients were ran-
domized into three groups, ie, sham injections, ranibizumab 
0.3 mg injections, and ranibizumab 0.5 mg injections. The 
primary outcomes assessed were the proportion of subjects 
who gain at least 15 letters in BCVA compared with baseline, 
mean change from baseline in BCVA, and mean change from 
baseline in central foveal thickness. The preliminary results 
show that patients gaining at least three lines compared 
with baseline were 18.1%, 44.8%, and 39.2% in the RISE 
study and 12.3%, 33.6%, and 45.7% in the RIDE study in 
the sham, 0.3 mg ranibizumab, and 0.5 mg ranibizumab 
groups, respectively. Subjects achieving a visual acuity of 
at least 20/40 were 37.8%, 60%, and 63.2% in the RISE 
study, and 34.6%, 54.4%, and 62.2% in the RIDE study in 
the sham, 0.3 mg ranibizumab, and 0.5 mg ranibizumab 
groups, respectively. An analysis of the 24-month data from 
the two studies showed an ocular and general safety profile 
similar to previous trials, with no adverse effects due to 
ranibizumab injections.
RESOLVE study
RESOLVE is a randomized, double-masked, multicenter, 
Phase II study assessing the safety and efficacy of two 
concentrations of ranibizumab compared with nontreatment 
control for the treatment of diabetic macular edema in 
151 patients with clinically significant diabetic macular 
edema. Patients with a central macular thickness of 300 µm or 
greater were randomized to receive three-monthly intravitreal 
injections with either 0.3 mg or 0.5 mg ranibizumab, or 
placebo. After the three-monthly intravitreal injections, 
treatment was administered on an as-needed basis for 
nine months. The primary endpoint was the change in visual 
function at the end of follow-up. The study design allowed the 
investigator to double the dose of ranibizumab if resolution of 
macular edema was incomplete after one month. Moreover, 
retinal photocoagulation could be administered if needed.16,17 
During the 12 months of follow-up, mean BCVA increased 
and mean central retinal thickness decreased continuously 
over time. Mean change in BCVA from baseline to the 
12-month examination was −1.4 letters in the sham group. 
The groups receiving ranibizumab gained 10.3 letters. The 
proportion of patients who gained $10 letters and $15 
letters was three-fold higher in the ranibizumab arm 
compared with the sham arm. Mean change in central retinal 
thickness from baseline to month 12 was significantly higher 
in the ranibizumab group with respect to the sham group 
(−194.2 µm versus −48.4 µm, respectively, P , 0.0001). 
Safety data were consistent with previous studies of 
intravitreal ranibizumab. The mean number of injections 
administered during 12 months was 10.2 and 8.9 for 
ranibizumab and sham, respectively.
RESTORE study
Focal or grid laser is currently considered the standard of care 
in diabetic macular edema. The RESTORE study18 enrolled 
345 patients affected by diabetic macular edema to compare the 
effects secondary to laser treatment, ranibizumab injections, 
or combination of the two treatments. All patients were 
randomized to three groups, ie, ranibizumab and sham laser 
(n = 116), ranibizumab and laser photocoagulation (n = 118), 
or sham injections and laser (n = 111). Patients received 
three initial consecutive monthly injections followed by other 
injections on a prn basis, and laser/sham laser was performed 
at baseline. Retreatments were given in accordance with Early 
Treatment Diabetic Retinopathy Study (ETDRS) guidelines 
at intervals no shorter than three months from the previous 
treatment if considered necessary by the investigator. After 
12 months, a significantly greater proportion of patients had 
a BCVA letter score $15 and BCVA letter score level . 73 
(20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, 
respectively) and ranibizumab + laser (22.9% and 44.9%) 
versus laser alone (8.2% and 23.6%). Similar results could 
be found evaluating fluorescein angiography. A significantly 
larger proportion of patients who underwent ranibizumab 
injections alone or ranibizumab injections associated with laser 
treatment obtained total resolution of leakage compared with 
the laser group (19.4% and 13.7% versus 2.2%). Additionally, 
the mean central retinal thickness changed significantly 
at the 12-month follow-up (118.7 µm, P = 0.0002 and 
128.3 µm, P , 0.0001 in the first two groups versus 61.3 µm 
in the laser group). At one year of follow-up, no significant 
differences were detected between ranibizumab monotherapy 
and ranibizumab associated with laser photocoagulation. 
No cases of endophthalmitis occurred, and the patients who 
underwent ranibizumab treatment did not have an increased 
risk of cardiovascular or cerebrovascular events in this study. 
Between months 3 and 11, patients received an average of 
4.1 ranibizumab intravitreal injections in the ranibizumab arm, 
3.8 in the ranibizumab + laser arm, and 4.5 sham injections in 
the laser-treated arm.
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DRCRnet study
It is well known that corticosteroids may also play an 
important role in reducing diabetic macular edema19,20 by 
decreasing the release of arachidonic acid derivates, such 
as prostaglandins, that are responsible for altered retinal 
vascular permeability and inhibition of VEGF production.
The Diabetic Retinopathy Clinical Research Network 
(DRCRnet) has designed a randomized, multicenter clini-
cal trial to confirm the role of steroids and anti-VEGF drugs 
to compare these new forms of treatment with conventional 
laser.21,22 The study (with two years of follow-up) enrolled 691 
patients and examined a total of 854 eyes randomized into 
four groups receiving laser treatment alone (293 eyes), 0.5 mg 
ranibizumab + prompt laser photocoagulation (187 eyes), 0.5 mg 
ranibizumab + deferred laser (at least 24 weeks, 188 eyes), or 
intravitreal triamcinolone 4 mg + prompt laser (186 eyes).
At the one-year examination, the mean change in 
visual acuity letter score with respect to the baseline value 
showed a statistically significant improvement in the ranibi-
zumab + prompt laser group (+9 ± 11 letters, P , 0.001) and 
ranibizumab + deferred laser group (+9 ± 12, P , 0.001) 
but not in the triamcinolone + prompt laser group (+4 ± 13, 
P = 0.31) compared with the laser group (+3 ± 13). The study 
reported a similar reduction of diabetic macular edema in 
patients treated with triamcinolone or ranibizumab injections 
and a greater reduction in the patient group treated with laser 
photocoagulation alone.
Over the two years of follow-up, a different correlation 
between visual acuity change and retinal thickness was 
observed in each group. A progressive reduction in mean cen-
tral subfield thickness was noted in the laser group during the 
24 months of follow-up; however, the mean change in visual 
acuity did not continue to increase from the one-year visit to the 
two-year visit, as noted during the first year of follow-up.
In the triamcinolone + laser group, during the first year of 
follow-up, an improvement of visual function was associated 
with a significant reduction in central subfield thickness, 
whereas from the one-year to two-year examination, the 
mean central subfield thickness increased in parallel with 
visual acuity reduction. The ranibizumab groups showed a 
visual acuity improvement associated with a central subfield 
thickness reduction from baseline to the 12-month visit. In the 
following period, the optical coherence tomography results 
remained relatively stable up to the 24-month examination 
and paralleled the visual acuity outcomes during this time. 
Intraocular hypertension and cataract surgery were more 
frequently noted in the triamcinolone + prompt laser group 
in comparison with groups receiving ranibizumab + laser or 
laser alone. This trial confirms the promising preliminary 
results of ranibizumab in the treatment of diabetic macular 
edema and suggests that combined therapy might offer 
a more efficient approach, considering the multifactorial 
pathogenesis of the disorder. Table 1 summarizes the results 
of the major randomized clinical trials of ranibizumab.
Bevacizumab and ranibizumab
Recently, a new study23 compared the effects of bevacizumab 
and ranibizumab on visual acuity and macular thickness in 
eyes affected by diabetic macular edema. The study enrolled 
29 patients who received one single intravitreal injection of 
bevacizumab followed at least six months later by one single 
injection of ranibizumab. The study demonstrated how the two 
antiangiogenic factors are able to reduce macular thickness 
(from 411 µm to 373 µm at follow-up week 6 after bevaci-
zumab injection and from 428 µm to 279 µm at follow-up 
week 6 after ranibizumab injection), and improve visual acuity 
(from 59 ETDRS letters to 61.5 ETDRS letters at follow-up 
week 6 after bevacizumab injection and from 53 ETDRS letters 
to 66 ETDRS letters at follow-up week 6 after ranibizumab 
injection). Unfortunately, this study is characterized by a short 
follow-up period and a small number of enrolled patients.
Safety and complications
The MARINA24 and ANCHOR25,26 trials in neovascular 
age-related macular degeneration support the safety of 
intravitreal ranibizumab, and show no increase in systemic 
adverse effects. Pooled one-year safety data from PIER,27 
MARINA, and ANCHOR show an increased rate of vascular 
events (2.1% rate of myocardial infarction and stroke) in the 
ranibizumab arms versus the control group (1.1%). These 
differences may be clinically irrelevant, given the two-year 
safety data. Ocular adverse effects were rare, and similar to 
rates reported for intravitreal bevacizumab and pegaptanib.
The READ-2 study reported a single case of severe 
adverse events. One patient died of a cerebral vascular 
accident six weeks after the first ranibizumab injection. This 
event was considered unrelated to ranibizumab because of 
pre-existing cardiovascular disease and because a long period 
had elapsed between the injection and the vascular event. 
There were no statistically significant differences in mean 
systolic and diastolic blood pressure values between the 
groups. Ocular adverse events included vitreous hemorrhages 
in eight patients.13,14
The RESOLVE study17 showed no imbalances in the rates 
of ocular and nonocular severe adverse effects or adverse 
effects between patients receiving ranibizumab compared 
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with sham injections. The proportion of patients with   ocular 
severe adverse effects in the study eye was comparable 
between the treatment arms. Most of the severe adverse 
effects were nonocular in origin (ranibizumab 14 [13.7%] 
and sham eight [16.3%]). Endophthalmitis occurred in two 
patients out of the 102 receiving intravitreal ranibizumab 
injection. Also, the rate of subjects reporting nonocular 
adverse effects was comparable between the ranibizumab 
and sham arms, ie, 62.7% and 65.3%, respectively. In 
the RESTORE study,18 no cases of endophthalmitis were 
reported. Increased intraocular pressure was reported for 
one patient each in the ranibizumab arms. Ranibizumab 
monotherapy or combined with laser was not associated 
with an increased risk of cardiovascular or cerebrovascular 
events in this study.
Further, the DRCRnet study reported all complications 
collected during the two-year follow-up period.21 Three cases 
of endophthalmitis were described following ranibizumab 
injection, with an incidence of 0.08%, and one case of 
inflammatory pseudoendophthalmitis (0.5%) was reported. 
For all groups of patients enrolled in the study, there were 
no statistically significant differences for the incidence of 
systemic adverse events (3 ± 3 events in the sham group, 3 ± 3 
events in the two ranibizumab groups, and 3 ± 4 events in the 
triamcinolone group). The authors also reported a single case 
of progression of tractional retinal detachment occurring in 
the ranibizumab + deferred laser group.
Conclusion
The advent of intravitreal anti-VEGF drugs has opened up a 
new era in the management of diabetic macular edema. While 
focal/grid treatment remains a reference for the treatment 
of diabetic macular edema and is supported by evidence 
provided by large-scale studies, the use of anti-VEGF 
substances such as ranibizumab in clinical practice has shown 
encouraging results. Most of the studies reported in this 
review were well designed clinical trials with the objective of 
demonstrating both the therapeutic effect of ranibizumab and 
data regarding its safety (RESOLVE, RESTORE, DRCRnet, 
RIDE, and RISE). However, only larger trials can consolidate 
routine clinical use of anti-VEGF drugs, with the objective of 
creating standard guidelines for the management of diabetic 
macular edema. Another aspect that must be highlighted is 
the efficacy of anti-VEGF drugs over a long follow-up period. 
Most controlled studies focus on one-year or two-year results, 
so long-term results are unavailable. It would be of foremost 
importance to demonstrate that anti-VEGF drugs are able to 
provide therapeutic effects over a long period of time, and to 
compare these effects with those of laser treatment, which 
is characterized by a prolonged therapeutic effect that most 
likely is more efficient many years after its employment. 
The use of combination therapy, including ranibizumab 
and focal/grid laser treatment, shows encouraging results, 
as demonstrated by the READ-2, RESOLVE, RESTORE, 
and DRCRnet studies, and must also be evaluated over a 
Table 1 Comparative analyses of ranibizumab studies
Study 12 months 24 months
Letters  
gained
Percentage  
gaining 3 lines
Mean CRT  
reduction (μm)
Letters  
gained
Percentage  
gaining 3 lines
Mean CRT  
reduction (μm)
READ-2 Ranibizumab 0.2 mg 7.70 24
Laser −5.10 18
Combination 6.80 26
RESOLVE Ranibizumab 0.3–0.6 mg 9.2 18 200.7
Ranibizumab 0.5–1 mg 6.4 15 187.6
Sham −0.1 5 48.4
RESTORE Ranibizumab 0.5 mg 6.1 22.6 118.7
Combination 5.9 22.9 128.3
Laser 0.8 8.2 61.3
RISE Lucentis 0.3 mg 18.1
Lucentis 0.5 mg 44.8
Sham 39.2
RIDE Lucentis 0.3 mg 12.3
Lucentis 0.5 mg 33.6
Sham 45.7
DRCRnet Sham + prompt laser 3 15 102 3 18 138
Ranibizumab + prompt laser 9 30 131 7 29 141
Ranibizumab + deferred laser 9 28 137 9 28 150
Triamcinolone + prompt laser 4 21 127 2 22 107
Abbreviations: CRT, central retinal thickness; DRCTnet, Diabetic Retinopathy Clinical Research Network.
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long time span. The clinical trials to date have demonstrated 
an adequate safety profile for ranibizumab, although long-
term analysis of systemic and ocular side effects is needed. 
Therefore, it is important to control patients who undergo 
intravitreal injections of antiangiogenic drugs for diabetic 
macular edema carefully. Although severe ocular adverse 
events are unusual and rarely reported, the limited experience 
relating to the use of this new class of drugs requires all 
ophthalmologists to select patients carefully and to schedule 
strict follow-up examinations in order to detect short-term 
and long-term side effects promptly.
Disclosure
FB is a consultant for Novartis, Allergan, Pfizer, Alcon, 
Bayer, and Thea.
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